I agree with Charts on this one. Mayne Pharma at a turning point with disruption of global supply chains for medicines & many in short supply in the US. With the pandemic and huge demand for a range of medications by medical facilities and over the counter, I believe there has been a shift: it has become a sellers market & there will be an increasing emphasis on buying drugs manufactured locally . Also, I cannot believe a Director would fork out around $2 million in early March without feeling fairly confident in the short to medium term of Mayne Pharma. As a result, I started buying back in a few weeks ago on the basis that the SP could not go down much more. We will see..........
MYX Price at posting:
32.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)